Work

41P Safety of concurrent osimertinib (osi) and cranial radiotherapy (RT) in non-small cell lung cancer (NSCLC): Results from the phase IV SATIN trial

Year: 2026

Type: article

Abstract: Osi has high intracranial (IC) activity in epidermal growth factor receptor (EGFR)–NSCLC; yet patients (pts) may still develop IC-progressive disease (PD) requiring stereotactic radiotherapy (SRT) or whole-brain radiotherapy (WBRT). The safety of continuing osi during cranial RT, particularly regarding neurotoxicity, remains uncertain and was investigated in this study.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106348

Authors: J.W.J. Huijs, J.J.A.O. Schoenmaekers, A.J. van der Wekken, M.S. Paats, C. Wolfs, J. Dijkstra, M. Broen, S. Hashemi, B. Piet, C. van der Graaf, L. Brandts, A.J. De Langen, D. De Ruysscher, A-M.C. Dingemans, L. Hendriks

Institutions: Maastricht University Medical Centre, Maastricht University, University Medical Center Groningen, Erasmus MC, Amsterdam University Medical Centers, Amsterdam UMC Location Vrije Universiteit Amsterdam, Radboud University Nijmegen, Radboud University Medical Center, The Netherlands Cancer Institute, Maastro Clinic

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

Funders: AstraZeneca, Massachusetts General Hospital, Yale University, Memorial Sloan-Kettering Cancer Center, Universiteit Maastricht, Sungkyunkwan University, Maastricht Universitair Medisch Centrum, Samsung, Weill Cornell Medical College, University of Texas MD Anderson Cancer Center, Daiichi Sankyo Europe

OpenAlex ID: W7137993139

FWCI:

Cites:

Cited by:

Related to: